欢迎光临源叶生物,登录 | 注册 |
当前位置: 首页 > 小分子抑制剂 > Angiogenesis > KG-5

浏览历史

S89531

KG-5

源叶(MedMol) 98%
  • 英文名:
  • 2-(Methylthio)-6-[4-[5-[[3-(trifluoromethyl)phenyl]amino]-1H-1,2,4-triazol-3-yl]phenoxy]-4-pyrimidinamine
  • 别名:
  • KG-5; KG 5; KG5;
  • CAS号:
  • 877874-85-6
  • 分子式:
  • C20H16F3N7OS
  • 分子量:
  • 459.45
品牌货号产品规格价格(RMB) 库存(上海) 北京 武汉 南京 数量计量单位 加入购物车...
源叶(MedMol) S89531-5mg 98% ¥1130.00元 6 - - - EA 加入购物车
源叶(MedMol) S89531-10mg 98% ¥1800.00元 7 - - - EA 加入购物车
源叶(MedMol) S89531-25mg 98% ¥3600.00元 6 - - - EA 加入购物车
源叶(MedMol) S89531-100mg 98% ¥7500.00元 预计交期:2-3天 - - - EA 加入购物车
大包装询价

提交您的电话号码并同意《个人信息授权与保护申明》,到货后将短信提示。
提交

产品介绍

参考文献

质检证书(COA)

摩尔浓度计算器

相关产品

  • 产品描述: KG5 is an orally active dual PDGFRβ and B-Raf allosteric inhibitor. KG5 also inhibits Flt3, KIT and c-Raf. KG5 has anticancer, antiangiogenic activities
  • 靶点: PDGFRβ:520 nM (Kd);PDGFRα:300 nM (Kd);B-Raf;c-Raf;FLT3:52 nM (Kd);KIT:170 nM (Kd);Raf; FLT; PDGFR; c-Kit
  • 体外研究:
    KG5 (Compound 6) inhibits vascular smooth muscle cells (VSMCs) and endothelial cells viability with EC50 values of 0.59 μM and 0.54 μM, respectively. Compound 6 selectively blocks S338 phosphorylation, yet does not influence S259. KG5 (Compound 6) inhibits only PDGFRα and β with Kds of 300 and 520 nM, respectively, and Flt3 and KIT at 52 and 170 nM, respectively. KG5 (Compound 6; 5 μM) inhibits phosphorylation of MEK and ERK in endothelial cells stimulated with bFGF or VEGF
  • 体内研究:
    KG5 (Compound 6; 100 mg/kg; oral administration; daily; for 26 days) treatment prevents tumor growth in an orthotopic renal cell carcinoma model. KG5 (Compound 6; 50 mg/kg; i.p.; twice daily) treatment completely blocks angiogenesis relative to vehicle control in mice (injected with Matrigel containing bFGF). Pharmacokinetic analysis of the dose and formulation of KG5 used indicated a Cmax of 3.6 μg/mL, T1/2 of 11.5 h, and an area under the concentration time curve (AUC0-12h) of 14.7 μg•h/mL. KG5 (Compound 6; 1 μM) disrupts a late step in angiogenesis during zebrafish embryogenesis. Animal Model: Male Nu/Nu mice injected with SN12C-RFP cells Dosage: 100 mg/kg Administration: Oral administration; daily; for 26 days Result: Prevented tumor growth in an orthotopic renal cell carcinoma model.
  • 参考文献:
    1. Eric A Murphy, et al. Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRbeta/B-RAF. Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4299-304.
  • 溶解性: Soluble  in  DMSO
  • 保存条件: -20℃
  • 配置溶液浓度参考:
    1mg 5mg 10mg
    1 mM 2.177 ml 10.883 ml 21.765 ml
    5 mM 0.435 ml 2.177 ml 4.353 ml
    10 mM 0.218 ml 1.088 ml 2.177 ml
    50 mM 0.044 ml 0.218 ml 0.435 ml
  • 注意:部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。
输入产品批号:

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:


质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)


  • =
    *
    *


源叶所有产品仅用作科学研究,销售产品行为均适用于我司网上所列通用销售条款。